Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under Regulation 24A of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The report was prepared and certified by Sunil M. Dedhia, a Practising Company Secretary (FCS 3483), after reviewing the company's filings, website, records, and SEBI-related compliance for the year. All applicable SEBI regulations were examined, including Listing Obligations, Insider Trading, Takeover, Depositories, and Share-Based Employee Benefits norms. Every one of the 12 specific compliance parameters checked — such as Secretarial Standards, policy adoption, website disclosures, director qualifications, related-party transactions, and event disclosures — was marked as fully compliant (Yes) or not applicable. No deviations, penalties, SEBI/stock exchange actions, auditor resignations, or additional non-compliances were observed during the review period.
This is a routine annual regulatory filing with a clean bill of compliance — no negative observations, penalties, or governance flags were raised. For shareholders, this confirms the company has maintained strong corporate governance standards throughout FY25, which is a positive signal but unlikely to move the stock price on its own.